154 related articles for article (PubMed ID: 35178029)
1. Luteolin Potentially Treating Prostate Cancer and COVID-19 Analyzed by the Bioinformatics Approach: Clinical Findings and Drug Targets.
Ye Y; Huang Z; Chen M; Mo Y; Mo Z
Front Endocrinol (Lausanne); 2021; 12():802447. PubMed ID: 35178029
[TBL] [Abstract][Full Text] [Related]
2. A Practical Strategy for Exploring the Pharmacological Mechanism of Luteolin Against COVID-19/Asthma Comorbidity: Findings of System Pharmacology and Bioinformatics Analysis.
Xie YZ; Peng CW; Su ZQ; Huang HT; Liu XH; Zhan SF; Huang XF
Front Immunol; 2021; 12():769011. PubMed ID: 35069542
[TBL] [Abstract][Full Text] [Related]
3. Theoretical Study of the Molecular Mechanism of Maxingyigan Decoction Against COVID-19: Network Pharmacology-based Strategy.
Wang M; Fu D; Yao L; Li J
Comb Chem High Throughput Screen; 2021; 24(2):294-305. PubMed ID: 32767929
[TBL] [Abstract][Full Text] [Related]
4. Medical Significance of Uterine Corpus Endometrial Carcinoma Patients Infected With SARS-CoV-2 and Pharmacological Characteristics of Plumbagin.
Li Y; Yu S; Li Y; Liang X; Su M; Li R
Front Endocrinol (Lausanne); 2021; 12():714909. PubMed ID: 34712201
[TBL] [Abstract][Full Text] [Related]
5. Luteolin is a potential inhibitor of COVID-19: An in silico analysis.
Wang W; Yang C; Xia J; Li N; Xiong W
Medicine (Baltimore); 2023 Sep; 102(38):e35029. PubMed ID: 37746970
[TBL] [Abstract][Full Text] [Related]
6. New tale on LianHuaQingWen: IL6R/IL6/IL6ST complex is a potential target for COVID-19 treatment.
Tianyu Z; Xiaoli C; Yaru W; Min Z; Fengli Y; Kan H; Li C; Jing L
Aging (Albany NY); 2021 Nov; 13(21):23913-23935. PubMed ID: 34731090
[TBL] [Abstract][Full Text] [Related]
7. Identification of COVID-19 and Dengue Host Factor Interaction Networks Based on Integrative Bioinformatics Analyses.
Zheng W; Wu H; Liu C; Yan Q; Wang T; Wu P; Liu X; Jiang Y; Zhan S
Front Immunol; 2021; 12():707287. PubMed ID: 34394108
[TBL] [Abstract][Full Text] [Related]
8. Exploring the Potential Mechanism of Shufeng Jiedu Capsule for Treating COVID-19 by Comprehensive Network Pharmacological Approaches and Molecular Docking Validation.
Zhuang Z; Zhong X; Zhang H; Chen H; Huang B; Lin D; Wen J
Comb Chem High Throughput Screen; 2021; 24(9):1377-1394. PubMed ID: 33135607
[TBL] [Abstract][Full Text] [Related]
9. Potential effect of Maxing Shigan decoction against coronavirus disease 2019 (COVID-19) revealed by network pharmacology and experimental verification.
Li Y; Chu F; Li P; Johnson N; Li T; Wang Y; An R; Wu D; Chen J; Su Z; Gu X; Ding X
J Ethnopharmacol; 2021 May; 271():113854. PubMed ID: 33513419
[TBL] [Abstract][Full Text] [Related]
10. Network pharmacology and molecular docking analyses on Lianhua Qingwen capsule indicate Akt1 is a potential target to treat and prevent COVID-19.
Xia QD; Xun Y; Lu JL; Lu YC; Yang YY; Zhou P; Hu J; Li C; Wang SG
Cell Prolif; 2020 Dec; 53(12):e12949. PubMed ID: 33140889
[TBL] [Abstract][Full Text] [Related]
11. Network Pharmacology and bioinformatics analyses identify intersection genes of niacin and COVID-19 as potential therapeutic targets.
Li R; Li Y; Liang X; Yang L; Su M; Lai KP
Brief Bioinform; 2021 Mar; 22(2):1279-1290. PubMed ID: 33169132
[TBL] [Abstract][Full Text] [Related]
12. Exploration of the mechanism of luteolin against ischemic stroke based on network pharmacology, molecular docking and experimental verification.
Dong R; Huang R; Shi X; Xu Z; Mang J
Bioengineered; 2021 Dec; 12(2):12274-12293. PubMed ID: 34898370
[TBL] [Abstract][Full Text] [Related]
13. Identifying the molecular targets and mechanisms of xuebijing injection for the treatment of COVID-19 via network parmacology and molecular docking.
Tianyu Z; Liying G
Bioengineered; 2021 Dec; 12(1):2274-2287. PubMed ID: 34077310
[TBL] [Abstract][Full Text] [Related]
14. Network pharmacology for the identification of phytochemicals in traditional Chinese medicine for COVID-19 that may regulate interleukin-6.
Niu WH; Wu F; Cao WY; Wu ZG; Chao YC; Liang C
Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33146673
[TBL] [Abstract][Full Text] [Related]
15. Traditional Chinese medicine network pharmacology study on exploring the mechanism of Xuebijing Injection in the treatment of coronavirus disease 2019.
Xing Y; Hua YR; Shang J; Ge WH; Liao J
Chin J Nat Med; 2020 Dec; 18(12):941-951. PubMed ID: 33357725
[TBL] [Abstract][Full Text] [Related]
16. A network pharmacology strategy to investigate the anti-inflammatory mechanism of luteolin combined with in vitro transcriptomics and proteomics.
Huang XF; Zhang JL; Huang DP; Huang AS; Huang HT; Liu Q; Liu XH; Liao HL
Int Immunopharmacol; 2020 Sep; 86():106727. PubMed ID: 32593158
[TBL] [Abstract][Full Text] [Related]
17. Luteolin: a blocker of SARS-CoV-2 cell entry based on relaxed complex scheme, molecular dynamics simulation, and metadynamics.
Shadrack DM; Deogratias G; Kiruri LW; Onoka I; Vianney JM; Swai H; Nyandoro SS
J Mol Model; 2021 Jul; 27(8):221. PubMed ID: 34236507
[TBL] [Abstract][Full Text] [Related]
18. Luteolin and gefitinib regulation of EGF signaling pathway and cell cycle pathway genes in PC-3 human prostate cancer cells.
Markaverich BM; Vijjeswarapu M; Shoulars K; Rodriguez M
J Steroid Biochem Mol Biol; 2010 Oct; 122(4):219-31. PubMed ID: 20558290
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Mechanism of Xiaoqinglong Decoction against COVID-19 Based on Network Pharmacology and Molecular Docking Technology.
Li HL; Zhou JP; Deng JM
Comb Chem High Throughput Screen; 2022; 25(13):2264-2277. PubMed ID: 35227178
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
Nayak SK
Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
